Lebwohl, M., Strober, B., Scharnitz, T., Linaberry, M., Hoyt, K., Banerjee, S., Kisa, R.M. and Martin, G. 2023. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s244. DOI:https://doi.org/10.25251/skin.7.supp.244.